Cargando…
Molecular alterations of driver genes in non-small cell lung cancer: from diagnostics to targeted therapy
Lung cancer is the leading cause of cancer death all over the world. The majority (80-85 %) of lung cancer cases are classified as non-small cell lung cancer (NSCLC). Within NSCLC, adenocarcinoma (AC) and squamous cell carcinoma (SCC) are the most often recognized. The histological and immunohistoch...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Leibniz Research Centre for Working Environment and Human Factors
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10279966/ https://www.ncbi.nlm.nih.gov/pubmed/37346803 http://dx.doi.org/10.17179/excli2023-6122 |
_version_ | 1785060703986515968 |
---|---|
author | Grodzka, Anna Knopik-Skrocka, Agnieszka Kowalska, Katarzyna Kurzawa, Pawel Krzyzaniak, Monika Stencel, Katarzyna Bryl, Maciej |
author_facet | Grodzka, Anna Knopik-Skrocka, Agnieszka Kowalska, Katarzyna Kurzawa, Pawel Krzyzaniak, Monika Stencel, Katarzyna Bryl, Maciej |
author_sort | Grodzka, Anna |
collection | PubMed |
description | Lung cancer is the leading cause of cancer death all over the world. The majority (80-85 %) of lung cancer cases are classified as non-small cell lung cancer (NSCLC). Within NSCLC, adenocarcinoma (AC) and squamous cell carcinoma (SCC) are the most often recognized. The histological and immunohistochemical examination of NSCLC is a basic diagnostic tool, but insufficient for comprehensive therapeutic decisions. In some NSCLC patients, mainly adenocarcinoma, molecular alterations in driver genes, like EGFR, KRAS, HER2, ALK, MET, BRAF, RET, ROS1, and NTRK are recognized. The frequency of some of those changes is different depending on race, and between smokers and non-smokers. The molecular diagnostics of NSCLC using modern methods, like next-generation sequencing, is essential in estimating targeted, personalized therapy. In recent years, a breakthrough in understanding the importance of molecular studies for the precise treatment of NSCLC has been observed. Many new drugs were approved, including tyrosine kinase and immune checkpoint inhibitors. Clinical trials testing novel molecules like miRNAs and trials with CAR-T cells (chimeric antigen receptor - T cells) dedicated to NSCLC patients are ongoing. |
format | Online Article Text |
id | pubmed-10279966 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Leibniz Research Centre for Working Environment and Human Factors |
record_format | MEDLINE/PubMed |
spelling | pubmed-102799662023-06-21 Molecular alterations of driver genes in non-small cell lung cancer: from diagnostics to targeted therapy Grodzka, Anna Knopik-Skrocka, Agnieszka Kowalska, Katarzyna Kurzawa, Pawel Krzyzaniak, Monika Stencel, Katarzyna Bryl, Maciej EXCLI J Review Article Lung cancer is the leading cause of cancer death all over the world. The majority (80-85 %) of lung cancer cases are classified as non-small cell lung cancer (NSCLC). Within NSCLC, adenocarcinoma (AC) and squamous cell carcinoma (SCC) are the most often recognized. The histological and immunohistochemical examination of NSCLC is a basic diagnostic tool, but insufficient for comprehensive therapeutic decisions. In some NSCLC patients, mainly adenocarcinoma, molecular alterations in driver genes, like EGFR, KRAS, HER2, ALK, MET, BRAF, RET, ROS1, and NTRK are recognized. The frequency of some of those changes is different depending on race, and between smokers and non-smokers. The molecular diagnostics of NSCLC using modern methods, like next-generation sequencing, is essential in estimating targeted, personalized therapy. In recent years, a breakthrough in understanding the importance of molecular studies for the precise treatment of NSCLC has been observed. Many new drugs were approved, including tyrosine kinase and immune checkpoint inhibitors. Clinical trials testing novel molecules like miRNAs and trials with CAR-T cells (chimeric antigen receptor - T cells) dedicated to NSCLC patients are ongoing. Leibniz Research Centre for Working Environment and Human Factors 2023-05-11 /pmc/articles/PMC10279966/ /pubmed/37346803 http://dx.doi.org/10.17179/excli2023-6122 Text en Copyright © 2023 Grodzka et al. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution Licence (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ) You are free to copy, distribute and transmit the work, provided the original author and source are credited. |
spellingShingle | Review Article Grodzka, Anna Knopik-Skrocka, Agnieszka Kowalska, Katarzyna Kurzawa, Pawel Krzyzaniak, Monika Stencel, Katarzyna Bryl, Maciej Molecular alterations of driver genes in non-small cell lung cancer: from diagnostics to targeted therapy |
title | Molecular alterations of driver genes in non-small cell lung cancer: from diagnostics to targeted therapy |
title_full | Molecular alterations of driver genes in non-small cell lung cancer: from diagnostics to targeted therapy |
title_fullStr | Molecular alterations of driver genes in non-small cell lung cancer: from diagnostics to targeted therapy |
title_full_unstemmed | Molecular alterations of driver genes in non-small cell lung cancer: from diagnostics to targeted therapy |
title_short | Molecular alterations of driver genes in non-small cell lung cancer: from diagnostics to targeted therapy |
title_sort | molecular alterations of driver genes in non-small cell lung cancer: from diagnostics to targeted therapy |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10279966/ https://www.ncbi.nlm.nih.gov/pubmed/37346803 http://dx.doi.org/10.17179/excli2023-6122 |
work_keys_str_mv | AT grodzkaanna molecularalterationsofdrivergenesinnonsmallcelllungcancerfromdiagnosticstotargetedtherapy AT knopikskrockaagnieszka molecularalterationsofdrivergenesinnonsmallcelllungcancerfromdiagnosticstotargetedtherapy AT kowalskakatarzyna molecularalterationsofdrivergenesinnonsmallcelllungcancerfromdiagnosticstotargetedtherapy AT kurzawapawel molecularalterationsofdrivergenesinnonsmallcelllungcancerfromdiagnosticstotargetedtherapy AT krzyzaniakmonika molecularalterationsofdrivergenesinnonsmallcelllungcancerfromdiagnosticstotargetedtherapy AT stencelkatarzyna molecularalterationsofdrivergenesinnonsmallcelllungcancerfromdiagnosticstotargetedtherapy AT brylmaciej molecularalterationsofdrivergenesinnonsmallcelllungcancerfromdiagnosticstotargetedtherapy |